Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344597 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7156149 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL8590554 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL5350100 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL5390328 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7026542 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL3546297 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7154349 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL6949988 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL6956183 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104926898-A | Method for synthesizing various glucosides on basis of 4-methylumbelliferone | GUANGDONG INST MICROBIOLOGY | 2015-09-23 | — | — | CN | claimed |
| CN-119320758-A | Acetyl esterase KpACE derived from klebsiella pneumoniae and application thereof | 北京清华长庚医院 | 2025-01-17 | — | — | CN | disclosed |
| CN-119285591-A | Biaryl amides with modified sugar groups for the treatment of diseases related to the heat shock protein pathway | 里亚塔医药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240182507-A1 | BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY | REATA PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024051666-A1 | DIBENZYLBUTYROLACTONE GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2024-03-14 | — | — | WO | disclosed |
| CN-117645641-A | Dibenzyl butyrolactone glycoside compound, and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-03-05 | — | — | CN | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116348474-A | Azoline saccharide compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-27 | — | — | CN | disclosed |
| US-20220296555-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-09-22 | — | — | US | disclosed |
| US-7846903-B2 | cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| US-7258902-B2 | Chiral 3,4-dihydro-2H-pyran compounds | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-21 | — | — | US | disclosed |
| US-7258902-B2 | Chiral 3,4-dihydro-2H-pyran compounds | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-21 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20050230660-A1 | Chiral 3,4-dihydro-2h-pyran compounds | BASF AKTIENGESELLSCHAFT | 2005-10-20 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| US-4855417-A | Anomeric deacetylation | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD (IL) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050230660-A1 | Chiral 3,4-dihydro-2h-pyran compounds | HPD, DHPS, DDT | PTPN1 938/4885POLB 2582/4885GAA 2431/4885 |
| US-20220296555-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, CPT1A | PTPN1 2888/4885POLB 1667/4885GAA 76/4885 |
| US-20240182507-A1 | BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY | HSPA2, HSPA1A, HSP90AB1 | PTPN1 3873/4885POLB 2532/4885GAA 245/4885 |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | PTPN1 4309/4885POLB 1027/4885GAA 4866/4885 |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | PTPN1 4482/4885POLB 3229/4885GAA 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.